TLDR:
- Gameto, a biotechnology company focused on women’s health, raised $33M in Series B funding led by Two Sigma Ventures and RA Capital.
- The funding will be used for the clinical development of Fertilo, their novel investigational in vitro maturation (IVM) solution.
Article Summary:
Gameto, a NYC-based biotechnology company, secured $33M in Series B funding to advance treatment options in women’s health. The funding round, led by Two Sigma Ventures and RA Capital, with participation from existing investors like Insight Partners and Future Ventures, brought the total amount raised to $73M. The company plans to use the funds for the clinical development of Fertilo, an innovative in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) to mature eggs outside of the body.
Dr. Dina Radenkovic, Chief Executive Officer of Gameto, spearheads the development of Fertilo, which aims to make IVF and egg freezing safer, faster, and more accessible by reducing hormonal injections. Following promising discussions with the U.S. Food and Drug Administration, Gameto received tentative approval to proceed to Phase 3 trials. The funding will also support the commercial launches of Fertilo in Australia and Latin America, where the solution is already in clinical use.
The investor group included prominent names like Olivia Walton’s Ingeborg Investments, Stacey Bendet Eisner of alice + olivia, and Chelsea Hirschhorn of Frida. The company’s mission is to develop novel treatment solutions for women’s health, initially focusing on infertility. With the support of this Series B funding, Gameto is poised to continue advancing their research and development efforts in the realm of women’s health.
